Detection of Analytes in Samples Using Liposome-Amplified Luminescence and Magnetic Separation

• US 20080182235A1
• Filed: 01/30/2007
• Published: 07/31/2008
• Est. Priority Date: 01/30/2007
• Status: Abandoned Application

• Current Assignee: Cornell Research Foundation Incorporated (Cornell University), Celsis International Limited (Pathology Associates, Inc.)
• Original Assignee: Celsis International, PLC, Cornell University
• Inventors: Hearn, Andrew, Madden, Judith, Sellappan, Subramani, Zaytseva, Natalya V., Baeumner, Antje J.
• Application Number:
  US11/669,078
• Publication Number:
  US 20080182235A1
• Time in Patent Office: Days
• US Class Current: 435/5
• CPC Class Codes: G01N 33/5432 Liposomes or microcapsules

Abstract

The invention relates to the encapsulation of luminescence-related molecules, including but not limited to, adenosine triphosphate (ATP), adenylate kinase (AK), alkaline phosphatase (ALP), luminol and luciferin/luciferase cocktails, within liposomes. These liposomes can be employed to enhance the luminescence detection of microorganisms and compounds in various products and samples. The liposomes containing the luminescence-related molecules can bear a probe which has a specific sequence or structure that, in turn can be used to hybridize to, or couple with, a portion of the target analyte. Within the same assay, paramagnetic beads can bear a probe having a specific sequence or structure that, can hybridize to, or couple with, a second portion of the target analyte to create a complex of analyte bound to paramagnetic beads and liposomes. This type of assay can be often referred to as a ‘sandwich’ assay. Once the probes hybridize to, or couple with, their targets, a complex can be formed of the paramagnetic beads, the analyte, or portion thereof, and the liposomes. This complex can then be washed to remove those components that are non-hybridized or non-coupled. Then, the paramagnetic bead-analyte-liposome complexes can be isolated from the sample using magnetic separation techniques and can be treated so as to release their encapsulated ATP, AK or other luminescence-related compounds. The resulting luminescence can then be determined in a chemical assay. This determination can be qualitative (i.e., an absence/presence assay) or quantitative (i.e., which can measure a specific amount of analyte present). Through the use of a cocktail of probe types, the assay can also qualitatively or quantitatively measure the presence of more than one analyte simultaneously. This type of assay can be of commercial importance in clinical and forensic applications, the personal care, pharmaceutical, food and beverage markets, as well as in environmental sample assays.

Claims

1. A method for detecting an analyte comprising the steps of:

a) obtaining a sample potentially comprising an analyte;

b) providing liposomes comprising a luminescence-related amplificant encapsulated within said liposomes, a buffer and paramagnetic beads;

c) incubating said sample potentially comprising an analyte, said liposomes, and said paramagnetic beads to provide a complex of said paramagnetic beads, said analyte and said liposomes;

d) separating said complex from non-complexed paramagnetic beads and non-complexed liposomes;

e) treating said complex with a liposome extractant to release the contents of said liposomes to form an assay sample; and

f) measuring light via a luminescent means;

wherein said liposomes of step b) comprise at least one reporter probe;

wherein said paramagnetic beads of step b) comprise at least one capture probe, and wherein the presence of said analyte is determined by an amount of light emitted from said assay sample.

2. The method of claim 1, wherein the presence of said analyte can be determined qualitatively or quantitatively.

3. The method of claim 1, wherein said luminescence-related amplificant is selected from the group consisting of adenosine triphosphate (ATP), adenylate kinase (AK), luminol, alkaline phosphatase (ALP) and a luciferase/luciferin cocktail.

4. The method of claim 3, wherein, when said luminescence-related amplificant is AK, said luminescence assay is performed using luciferase, luciferin and adenosine diphosphate (ADP).

5. The method of claim 3, wherein, when said luminescence-related amplificant is ATP, said luminescence assay is performed using luciferase and luciferin.

6. The method of claim 3, wherein, when said luminescence-related amplificant is a luciferase/luciferin, said luminescence assay is performed using ATP.

7. The method of claim 1, wherein the analyte is selected from the group consisting of bacteria, fungi, viruses, modified gene sequences, gene products, immunogenic compounds and molecular markers.

8. The method of claim 7, wherein the analyte comprises RNA, DNA, an antibody or an antigen.

9. The method of claim 8, wherein said RNA, said DNA or said antigen is isolated by removal from said analyte with a liposome extractant solution.

10. The method of claim 1, wherein the paramagnetic bead bound liposomes are washed with a wash buffer prior to removal of the contents of said liposomes.

11. The method of claim 1, wherein the separating of step d) is performed using a device comprising means for paramagnetic capture.

12. The method of claim 1, wherein the liposome extractant comprises a surface-active gluconate compound or derivative and an ethylene-amine compound or derivative.

13. The method of claim 12, wherein the liposome extractant does not chemically and/or adversely affect subsequent detection reactions.

14. The method of claim 1, wherein said paramagnetic beads and said capture probe are labeled.

15. The method of claim 14, wherein said paramagnetic beads are labeled with biotin and said capture probe is labeled with streptavidin.

16. The method of claim 14, wherein said paramagnetic beads are labeled with streptavidin and said capture probe is labeled with biotin.

17. The method of claim 1, wherein said sample is selected from the group consisting of a water sample, a biological sample, a food sample, a beverage sample, an air sample, a nutrient medium sample and a clinical sample.

18. The method of claim 1 wherein the liposomes have a diameter of between about 150 microns and about 400 microns.

19. The method of claim 18, wherein the diameter of said liposomes is selected to vary assay sensitivity.

20. The method of claim 1, wherein said liposomes are unilamellar or multilamellar.

21. The method of claim 1, wherein said at least one reporter probe is a cocktail of probes.

22. The method of claim 1, wherein said at least one reporter probe is specific for a target nucleic acid sequence or antigen.

23. A kit for the detection of analytes in a sample comprising

a) at least one buffer;

b) liposomes, wherein said liposomes comprise an encapsulated amplificant and comprise at least one reporter probe on the surface of said liposomes;

c) at least one probe;

d) paramagnetic beads, wherein said paramagnetic beads comprise at least one capture probe;

e) a liposome extractant;

f) at least one luminescence reagent.

24. The kit of claim 23, wherein said encapsulated amplificant is selected from the group consisting of adenosine triphosphate (ATP), adenylate kinase (AK), luminol and a luciferase/luciferin cocktail.

25. The kit of claim 23, wherein said at least one reporter probe is a cocktail of probes.

26. The kit of claim 23, wherein said at least one reporter probe is specific for a target nucleic acid sequence or antigen.

27. The kit of claim 23, wherein said paramagnetic beads and said capture probe are labeled.

28. The kit of claim 27, wherein said paramagnetic beads are labeled with biotin and said capture probe is labeled with streptavidin.

29. The kit of claim 27, wherein said paramagnetic beads are labeled with streptavidin and said capture probe is labeled with biotin.

30. The kit of claim 23, wherein said luminescence reagent is selected from the group consisting of luciferase, luciferin and adenosine diphosphate;

luciferase and luciferin; and

ATP.

31. The kit of claim 23, wherein said liposomes are unilamellar or multilamellar.

32. The kit of claim 23, wherein the liposome extractant comprises a surface-active gluconate compound or derivative and an ethylene-amine compound or derivative.

33. The kit of claim 32, wherein the liposome extractant does not chemically and/or adversely affect subsequent detection reactions.

34. The kit of claim 23, further comprising a liposome extractant solution.

35. The kit of claim 23, further comprising a device comprising means for magnetic capture.

36. The kit of claim 23, further comprising a negative and positive control.

37. The kit of claim 23, further comprising written instructions for using said kit.